CPRC
ABBV icon

Consolidated Portfolio Review Corp’s AbbVie ABBV Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,414
Closed -$559K – 36
2025
Q3 		$559K Buy
2,414
+41
+2% +$8.35K 0.07% 251
2025
Q2 		$441K Buy
2,373
+237
+11% +$44K 0.06% 275
2025
Q1 		$448K Buy
2,136
+150
+8% +$29.2K 0.07% 240
2024
Q4 		$353K Buy
1,986
+389
+24% +$71.5K 0.06% 271
2024
Q3 		$315K Sell
1,597
-541
-25% -$101K 0.07% 240
2024
Q2 		$367K Buy
2,138
+283
+15% +$46.9K 0.09% 203
2024
Q1 		$338K Sell
1,855
-1,198
-39% -$206K 0.09% 197
2023
Q4 		$473K Sell
3,053
-194
-6% -$28.3K 0.11% 178
2023
Q3 		$484K Buy
3,247
+106
+3% +$15.6K 0.12% 172
2023
Q2 		$423K Sell
3,141
-1
-0% -$147 0.1% 179
2023
Q1 		$501K Buy
+3,142
New +$480K 0.14% 159

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Consolidated Portfolio Review Corp's ABBV Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 2,414 shares — an estimated $559K sold.

Consolidated Portfolio Review Corp first reported a position in ABBV in Q1 2023 and held it in 11 quarters. The position peaked at $559K in Q3 2025. 4,146 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 2,414 AbbVie shares in Q4 2025, an estimated $559K.
  • Consolidated Portfolio Review Corp first reported a position in AbbVie in Q1 2023 and held it in 11 quarters.
  • Consolidated Portfolio Review Corp's AbbVie position peaked at $559K in Q3 2025.
  • 4,146 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.